Expression	O
of	O
SART3	B-protein
antigen	I-protein
and	O
induction	O
of	O
CTLs	B-cell_type
by	O
SART3-derived	O
peptides	O
in	O
breast	O
cancer	O
patients	O
.	O

We	O
recently	O
reported	O
the	O
SART3	B-protein
tumour-rejection	I-protein
antigen	I-protein
as	O
possessing	O
tumour	O
epitopes	O
capable	O
of	O
inducing	O
HLA-class	B-cell_type
I-restricted	I-cell_type
cytotoxic	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
(	O
CTLs	B-cell_type
)	O
.	O

This	O
study	O
investigated	O
expression	O
of	O
the	O
SART3	B-protein
antigen	I-protein
in	O
breast	O
cancer	O
to	O
explore	O
an	O
appropriate	O
molecule	O
for	O
use	O
in	O
specific	O
immunotherapy	O
of	O
breast	O
cancer	O
patients	O
.	O

The	O
SART3	B-protein
antigen	I-protein
was	O
detected	O
in	O
all	O
of	O
the	O
breast	B-cell_line
cancer	I-cell_line
cell	I-cell_line
lines	I-cell_line
tested	O
,	O
30	O
of	O
40	O
(	O
75	O
%	O
)	O
breast	O
cancer	O
tissue	O
samples	O
,	O
and	O
0	O
of	O
3	O
non-tumourous	O
breast	O
tissue	O
samples	O
.	O

SART3	O
derived	O
peptides	O
at	O
positions	B-DNA
109-118	I-DNA
and	I-DNA
315-323	I-DNA
induced	O
HLA-A24	O
restricted	O
CTLs	B-cell_type
that	O
reacted	O
to	O
breast	B-cell_type
cancer	I-cell_type
cells	I-cell_type
from	O
the	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
of	O
breast	O
cancer	O
patients	O
.	O

Therefore	O
,	O
the	O
SART3	B-protein
antigen	I-protein
and	O
its	O
peptides	O
could	O
be	O
an	O
appropriate	O
molecule	O
for	O
use	O
in	O
specific	O
immunotherapy	O
of	O
the	O
majority	O
of	O
HLA-A24-positive	O
breast	O
cancer	O
patients	O

British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
2001	NULL
)	NULL
84	NULL
(	NULL
7	NULL
)	NULL
,	NULL
915-919	NULL
©2001	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
®	NULL
doi	NULL
:	NULL
10.1054/	NULL
bjoc.2000.1690	NULL
,	NULL
available	NULL
online	NULL
at	NULL
http	NULL
:	NULL
/www.idealibrary.com	NULL
on	NULL
IDE	NULL
kl	NULL
.	NULL

http	NULL
:	NULL
//www.bjcancer.com	NULL
Expression	NULL
of	NULL
SART3	NULL
antigen	NULL
and	NULL
induction	NULL
of	NULL
CTLs	NULL
by	NULL
SART3-derived	NULL
peptides	NULL
in	NULL
breast	NULL
cancer	NULL
patients	NULL
Y	NULL
Suefuji	NULL
'	NULL
,	NULL
T	NULL
Sasatomi	NULL
'	NULL
,	NULL
S	NULL
Shichijo®	NULL
,	NULL
S	NULL
Nakagawa*	NULL
,	NULL
H	NULL
Deguchi	NULL
,	NULL
T	NULL
Koga®	NULL
,	NULL
T	NULL
Kameyama	NULL
'	NULL
and	NULL
K	NULL
Itoh®	NULL
Departments	NULL
of	NULL
'Oral	NULL
and	NULL
Maxillofacial	NULL
Surgery	NULL
,	NULL
*Surgery	NULL
,	NULL
and	NULL
Immunology	NULL
,	NULL
Kurume	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Kurume	NULL
,	NULL
Fukuoka	NULL
,	NULL
Japan	NULL
Summary	NULL
We	NULL
recently	NULL
reported	NULL
the	NULL
SART3	NULL
tumour-rejection	NULL
antigen	NULL
as	NULL
possessing	NULL
tumour	NULL
epitopes	NULL
capable	NULL
of	NULL
inducing	NULL
HLA-class	NULL
l-restricted	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
(	NULL
CTLs	NULL
)	NULL
.	NULL

This	NULL
study	NULL
investigated	NULL
expression	NULL
of	NULL
the	NULL
SART3	NULL
antigen	NULL
in	NULL
breast	NULL
cancer	NULL
to	NULL
explore	NULL
an	NULL
appropriate	NULL
molecule	NULL
for	NULL
use	NULL
in	NULL
specific	NULL
immunotherapy	NULL
of	NULL
breast	NULL
cancer	NULL
patients	NULL
.	NULL

The	NULL
SART3	NULL
antigen	NULL
was	NULL
detected	NULL
in	NULL
all	NULL
of	NULL
the	NULL
breast	NULL
cancer	NULL
cell	NULL
lines	NULL
tested	NULL
,	NULL
30	NULL
of	NULL
40	NULL
(	NULL
75	NULL
%	NULL
)	NULL
breast	NULL
cancer	NULL
tissue	NULL
samples	NULL
,	NULL
and	NULL
0	NULL
of	NULL
3	NULL
non-tumourous	NULL
breast	NULL
tissue	NULL
samples	NULL
.	NULL

SART3	NULL
derived	NULL
peptides	NULL
at	NULL
positions	NULL
109-118	NULL
and	NULL
315-323	NULL
induced	NULL
HLA-A24	NULL
restricted	NULL
CTLs	NULL
that	NULL
reacted	NULL
to	NULL
breast	NULL
cancer	NULL
cells	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
of	NULL
breast	NULL
cancer	NULL
patients	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
SART3	NULL
antigen	NULL
and	NULL
its	NULL
peptides	NULL
could	NULL
be	NULL
an	NULL
appropriate	NULL
molecule	NULL
for	NULL
use	NULL
in	NULL
specific	NULL
immunotherapy	NULL
of	NULL
the	NULL
majority	NULL
of	NULL
HLA-A24-positive	NULL
breast	NULL
cancer	NULL
patients	NULL
.	NULL

©	NULL
2001	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
-	NULL
http	NULL
:	NULL
//www.bjcancer.com	NULL
Keywords	NULL
:	NULL
SART3	NULL
antigen	NULL
;	NULL
breast	NULL
cancer	NULL
;	NULL
HLA-A24	NULL
;	NULL
immunotherapy	NULL
;	NULL
cancer	NULL
vaccine	NULL
The	NULL
incidence	NULL
of	NULL
breast	NULL
cancer	NULL
has	NULL
been	NULL
increasing	NULL
since	NULL
the	NULL
1960s	NULL
at	NULL
the	NULL
global	NULL
level	NULL
.	NULL

The	NULL
5-year	NULL
survival	NULL
rate	NULL
is	NULL
generally	NULL
low	NULL
in	NULL
stage	NULL
III	NULL
breast	NULL
cancer	NULL
patients	NULL
,	NULL
and	NULL
extremely	NULL
low	NULL
in	NULL
the	NULL
stage	NULL
IV	NULL
patients	NULL
,	NULL
regardless	NULL
of	NULL
different	NULL
treatment	NULL
modalities	NULL
including	NULL
hormone	NULL
therapy	NULL
,	NULL
chemotherapy	NULL
and	NULL
radiotherapy	NULL
.	NULL

Therefore	NULL
,	NULL
development	NULL
of	NULL
new	NULL
treatment	NULL
modalities	NULL
is	NULL
needed	NULL
,	NULL
and	NULL
one	NULL
of	NULL
them	NULL
will	NULL
be	NULL
specific	NULL
immunotherapy	NULL
(	NULL
Nestle	NULL
et	NULL
al	NULL
,	NULL
1998	NULL
;	NULL
Rosenberg	NULL
et	NULL
al	NULL
,	NULL
1998	NULL
;	NULL
Marchant	NULL
et	NULL
al	NULL
,	NULL
1999	NULL
)	NULL
.	NULL

However	NULL
,	NULL
little	NULL
information	NULL
is	NULL
available	NULL
regarding	NULL
tumour-rejection	NULL
antigens	NULL
on	NULL
breast	NULL
cancers	NULL
.	NULL

Many	NULL
tumour-rejection	NULL
antigens	NULL
have	NULL
been	NULL
identified	NULL
from	NULL
melanomas	NULL
(	NULL
van	NULL
der	NULL
Bruggen	NULL
et	NULL
al	NULL
,	NULL
1991	NULL
,	NULL
1994	NULL
;	NULL
Traversari	NULL
et	NULL
al	NULL
,	NULL
1992	NULL
;	NULL
Kawakami	NULL
et	NULL
al	NULL
,	NULL
1994	NULL
,	NULL
1995	NULL
;	NULL
Robbins	NULL
et	NULL
al	NULL
,	NULL
1996	NULL
,	NULL
1997	NULL
)	NULL
,	NULL
but	NULL
these	NULL
antigens	NULL
were	NULL
rarely	NULL
expressed	NULL
in	NULL
breast	NULL
cancers	NULL
(	NULL
Vincenzo	NULL
et	NULL
al	NULL
,	NULL
1995	NULL
)	NULL
.	NULL

SART1	NULL
,	NULL
,	NULL
,	NULL
antigen	NULL
that	NULL
was	NULL
identified	NULL
from	NULL
an	NULL
oesophageal	NULL
cancer	NULL
was	NULL
also	NULL
rarely	NULL
expressed	NULL
in	NULL
breast	NULL
cancers	NULL
(	NULL
Kawamoto	NULL
et	NULL
al	NULL
,	NULL
1999	NULL
)	NULL
.	NULL

MUCI1	NULL
antigen	NULL
and	NULL
HER2/neu	NULL
oncogene	NULL
products	NULL
might	NULL
encode	NULL
a	NULL
tumour	NULL
epitope	NULL
on	NULL
HLA-A2*	NULL
breast	NULL
cancers	NULL
(	NULL
David	NULL
et	NULL
al	NULL
,	NULL
1995	NULL
;	NULL
Reddish	NULL
et	NULL
al	NULL
,	NULL
1998	NULL
)	NULL
,	NULL
but	NULL
the	NULL
peptide	NULL
specificity	NULL
and	NULL
HLA-restriction	NULL
have	NULL
not	NULL
been	NULL
clearly	NULL
demon-strated	NULL
.	NULL

We	NULL
recently	NULL
reported	NULL
that	NULL
the	NULL
SART3	NULL
tumour-rejection	NULL
antigen	NULL
possesses	NULL
tumour	NULL
epitopes	NULL
capable	NULL
of	NULL
inducing	NULL
HLA-A24-restricted	NULL
CTLs	NULL
in	NULL
head	NULL
and	NULL
neck	NULL
cancer	NULL
patients	NULL
(	NULL
Yang	NULL
et	NULL
al	NULL
,	NULL
1999	NULL
)	NULL
.	NULL

The	NULL
140	NULL
kD	NULL
of	NULL
the	NULL
SART3	NULL
antigen	NULL
was	NULL
expressed	NULL
in	NULL
the	NULL
nucleus	NULL
of	NULL
all	NULL
of	NULL
the	NULL
malignant	NULL
cell	NULL
lines	NULL
and	NULL
in	NULL
the	NULL
majority	NULL
of	NULL
cancer	NULL
tissues	NULL
tested	NULL
,	NULL
but	NULL
not	NULL
in	NULL
the	NULL
nucleus	NULL
of	NULL
any	NULL
of	NULL
the	NULL
normal	NULL
tissues	NULL
except	NULL
that	NULL
of	NULL
the	NULL
testis	NULL
.	NULL

It	NULL
was	NULL
also	NULL
expressed	NULL
in	NULL
the	NULL
cytosol	NULL
of	NULL
the	NULL
majority	NULL
of	NULL
proliferating	NULL
cells	NULL
,	NULL
including	NULL
normal	NULL
cells	NULL
and	NULL
malignant	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
investigated	NULL
expression	NULL
of	NULL
the	NULL
SART3	NULL
antigen	NULL
in	NULL
breast	NULL
cancer	NULL
tissues	NULL
to	NULL
explore	NULL
for	NULL
an	NULL
appropriate	NULL
molecule	NULL
useful	NULL
for	NULL
specific	NULL
immunotherapy	NULL
of	NULL
breast	NULL
cancer	NULL
,	NULL
and	NULL
found	NULL
Received	NULL
25	NULL
July	NULL
2000	NULL
Revised	NULL
21	NULL
December	NULL
2000	NULL
Accepted	NULL
21	NULL
December	NULL
2000	NULL
Correspondence	NULL
to	NULL
:	NULL
K	NULL
Itoh	NULL
:	NULL
Email	NULL
:	NULL
Kyogo	NULL
@	NULL
med.kurume-u.ac.jp	NULL
evidence	NULL
suggesting	NULL
that	NULL
the	NULL
SART3	NULL
could	NULL
be	NULL
an	NULL
appropriate	NULL
target	NULL
molecule	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Samples	NULL
The	NULL
eight	NULL
breast	NULL
cancer	NULL
cell	NULL
lines	NULL
used	NULL
in	NULL
this	NULL
study	NULL
were	NULL
MCF7	NULL
,	NULL
R27	NULL
,	NULL
OCUB-M	NULL
,	NULL
OCUB-F	NULL
,	NULL
YMB-1-E	NULL
,	NULL
CRL1500	NULL
,	NULL
MDA-MB-231	NULL
and	NULL
T-47D	NULL
.	NULL

These	NULL
cell	NULL
lines	NULL
were	NULL
incubated	NULL
with	NULL
RPMI	NULL
1640	NULL
medium	NULL
,	NULL
EME	NULL
medium	NULL
,	NULL
or	NULL
Dulbecco	NULL
's	NULL
Modified	NULL
Eagle	NULL
's	NULL
Medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
,	NULL
included	NULL
in	NULL
these	NULL
cell	NULL
lines	NULL
reported	NULL
(	NULL
Kawamoto	NULL
et	NULL
al	NULL
,	NULL
1999	NULL
)	NULL
.	NULL

The	NULL
HLA-A2402*	NULL
tumours	NULL
are	NULL
OCUB-M	NULL
and	NULL
OCUB-FE	NULL
.	NULL

Breast	NULL
cancer	NULL
tissue	NULL
samples	NULL
(	NULL
n	NULL
=	NULL
40	NULL
)	NULL
and	NULL
non-tumourous	NULL
breast	NULL
tissue	NULL
samples	NULL
(	NULL
n	NULL
=	NULL
3	NULL
)	NULL
were	NULL
obtained	NULL
at	NULL
the	NULL
time	NULL
of	NULL
surgery	NULL
in	NULL
the	NULL
Kurume	NULL
University	NULL
Hospital	NULL
.	NULL

All	NULL
of	NULL
the	NULL
cancers	NULL
were	NULL
histologically	NULL
determined	NULL
to	NULL
be	NULL
adenocarcinoma	NULL
.	NULL

In	NULL
samples	NULL
,	NULL
stage	NULL
I	NULL
and	NULL
stage	NULL
II	NULL
group	NULL
numbered	NULL
23	NULL
cases	NULL
and	NULL
stage	NULL
III	NULL
and	NULL
stage	NULL
IV	NULL
numbered	NULL
17	NULL
cases	NULL
.	NULL

A	NULL
section	NULL
of	NULL
each	NULL
sample	NULL
was	NULL
minced	NULL
with	NULL
scissors	NULL
and	NULL
kept	NULL
at	NULL
-80°C	NULL
until	NULL
use	NULL
.	NULL

The	NULL
KE	NULL
-4	NULL
oesophageal	NULL
squamous	NULL
carcinoma	NULL
cell	NULL
line	NULL
(	NULL
HLA-A2402/A2601	NULL
)	NULL
from	NULL
which	NULL
the	NULL
SART3	NULL
was	NULL
cloned	NULL
(	NULL
Yang	NULL
et	NULL
al	NULL
,	NULL
1999	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
.	NULL

VA13	NULL
fibroblast	NULL
cells	NULL
(	NULL
no	NULL
expression	NULL
of	NULL
HLA-class	NULL
I	NULL
alleles	NULL
)	NULL
,	NULL
and	NULL
CIR-A402	NULL
cells	NULL
were	NULL
used	NULL
as	NULL
target	NULL
cells	NULL
as	NULL
negative	NULL
controls	NULL
,	NULL
as	NULL
reported	NULL
previously	NULL
(	NULL
Yang	NULL
et	NULL
al	NULL
,	NULL
1999	NULL
;	NULL
Murayama	NULL
et	NULL
al	NULL
.	NULL

2000	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
Expression	NULL
of	NULL
the	NULL
SART3	NULL
antigen	NULL
in	NULL
samples	NULL
was	NULL
investigated	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
using	NULL
the	NULL
polyclonal	NULL
anti-SART3	NULL
antibody	NULL
as	NULL
reported	NULL
previously	NULL
(	NULL
Yang	NULL
et	NULL
al	NULL
,	NULL
1999	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
oestrogen	NULL
and	NULL
progesterone	NULL
receptors	NULL
Expression	NULL
of	NULL
the	NULL
oestrogen	NULL
or	NULL
progesterone	NULL
receptors	NULL
in	NULL
frozen	NULL
sections	NULL
was	NULL
measured	NULL
using	NULL
the	NULL
standard	NULL
enzyme	NULL
immunoassay	NULL
commercially	NULL
available	NULL
from	NULL
SRL	NULL
(	NULL
Tokyo	NULL
)	NULL
.	NULL

For	NULL
the	NULL
assays	NULL
Abbot	NULL
915	NULL
916	NULL
Y	NULL
Suefuji	NULL
et	NULL
al	NULL
ER-EIA	NULL
mAb	NULL
or	NULL
Abbott	NULL
PgR-EIA	NULL
mAb	NULL
(	NULL
Abbott	NULL
Park	NULL
)	NULL
was	NULL
used	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

The	NULL
international	NULL
UICC-TNM	NULL
system	NULL
was	NULL
used	NULL
for	NULL
staging	NULL
the	NULL
31	NULL
breast	NULL
cancer	NULL
patients	NULL
.	NULL

Peptides	NULL
and	NULL
CTL	NULL
induction	NULL
The	NULL
SART3	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
(	NULL
VYDYNCHVDL	NULL
)	NULL
and	NULL
SART3	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
(	NULL
AYID-FEMKI	NULL
)	NULL
peptides	NULL
were	NULL
used	NULL
for	NULL
CTL	NULL
induction	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
Yang	NULL
et	NULL
al	NULL
,	NULL
1999	NULL
)	NULL
.	NULL

PBMCs	NULL
from	NULL
breast	NULL
cancer	NULL
patients	NULL
(	NULL
n	NULL
=	NULL
4	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
10	NULL
uM	NULL
of	NULL
a	NULL
peptide	NULL
in	NULL
one	NULL
well	NULL
of	NULL
a	NULL
24-well	NULL
plate	NULL
containing	NULL
2	NULL
ml	NULL
of	NULL
culture	NULL
medium	NULL
with	NULL
100	NULL
units	NULL
ml-	NULL
'	NULL
of	NULL
IL-2	NULL
(	NULL
Shiongi	NULL
Pharm	NULL
Co	NULL
,	NULL
Osaka	NULL
)	NULL
.	NULL

At	NULL
days	NULL
7	NULL
,	NULL
14	NULL
and	NULL
21	NULL
of	NULL
culture	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
washed	NULL
and	NULL
re-incubated	NULL
with	NULL
the	NULL
irradiated	NULL
(	NULL
45	NULL
Gy	NULL
)	NULL
autologous	NULL
PBMCs	NULL
acting	NULL
as	NULL
antigen-presenting	NULL
cells	NULL
,	NULL
which	NULL
had	NULL
been	NULL
pre-incubated	NULL
with	NULL
the	NULL
same	NULL
peptide	NULL
at	NULL
the	NULL
same	NULL
dose	NULL
for	NULL
3	NULL
h.	NULL
These	NULL
peptide-stimulated	NULL
PBMCs	NULL
(	NULL
2-3	NULL
x	NULL
10°	NULL
cells	NULL
well~	NULL
)	NULL
were	NULL
harvested	NULL
at	NULL
day	NULL
28	NULL
of	NULL
culture	NULL
,	NULL
and	NULL
further	NULL
cultured	NULL
in	NULL
a	NULL
96-well	NULL
U-bottom	NULL
microculture	NULL
plate	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
feeder	NULL
cells	NULL
(	NULL
irradiated	NULL
HLA-A24*	NULL
PBMCs	NULL
)	NULL
that	NULL
had	NULL
been	NULL
pre-pulsed	NULL
with	NULL
a	NULL
corresponding	NULL
peptide	NULL
in	NULL
order	NULL
to	NULL
obtain	NULL
large	NULL
numbers	NULL
of	NULL
effector	NULL
cells	NULL
.	NULL

Seven	NULL
to	NULL
10	NULL
days	NULL
later	NULL
,	NULL
the	NULL
expanded	NULL
cells	NULL
were	NULL
transferred	NULL
to	NULL
wells	NULL
of	NULL
a	NULL
24-well	NULL
plate	NULL
and	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
either	NULL
a	NULL
peptide	NULL
or	NULL
feeder	NULL
cells	NULL
for	NULL
an	NULL
additional	NULL
21-28	NULL
days	NULL
.	NULL

The	NULL
surface	NULL
phenotypes	NULL
and	NULL
CTL	NULL
activity	NULL
of	NULL
these	NULL
cells	NULL
was	NULL
tested	NULL
by	NULL
an	NULL
IFN-y	NULL
production	NULL
assay	NULL
(	NULL
limit	NULL
of	NULL
sensitivity	NULL
=	NULL
10	NULL
pg	NULL
ml-	NULL
'	NULL
)	NULL
,	NULL
and	NULL
©'Cr-labelled	NULL
assays	NULL
at	NULL
different	NULL
E	NULL
:	NULL
T	NULL
ratios	NULL
at	NULL
the	NULL
triplicate	NULL
assays	NULL
.	NULL

For	NULL
preparation	NULL
of	NULL
CTL	NULL
sublines	NULL
,	NULL
the	NULL
peptide-stimulated	NULL
PBMCs	NULL
were	NULL
incubated	NULL
at	NULL
1	NULL
or	NULL
10	NULL
or	NULL
100	NULL
cells	NULL
per	NULL
well	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
irradiated	NULL
HLA-A24	NULL
PBMCs	NULL
(	NULL
2-3	NULL
x	NULL
10°	NULL
cells	NULL
well	NULL
?	NULL
)	NULL

that	NULL
were	NULL
pre-loaded	NULL
with	NULL
a	NULL
relevant	NULL
peptide	NULL
,	NULL
followed	NULL
by	NULL
testing	NULL
of	NULL
their	NULL
surface	NULL
phenotype	NULL
and	NULL
CTL	NULL
activity	NULL
to	NULL
produce	NULL
IFN-y	NULL
in	NULL
response	NULL
to	NULL
CIR-A2402	NULL
pre-loaded	NULL
with	NULL
a	NULL
peptide	NULL
.	NULL

The	NULL
surface	NULL
phenotype	NULL
of	NULL
effector	NULL
cells	NULL
was	NULL
investigated	NULL
by	NULL
an	NULL
immunofluorescence	NULL
assay	NULL
with	NULL
FITC-conjugated	NULL
anti-CD3	NULL
,	NULL
-CD4	NULL
or	NULL
-CD8	NULL
mAb	NULL
(	NULL
Yang	NULL
et	NULL
al	NULL
,	NULL
1999	NULL
)	NULL
.	NULL

For	NULL
inhibition	NULL
of	NULL
CTL	NULL
activity	NULL
,	NULL
20	NULL
mg	NULL
ml-	NULL
'	NULL
of	NULL
anti-class	NULL
I	NULL
(	NULL
W6/32	NULL
,	NULL
IgG2a	NULL
)	NULL
or	NULL
anti-CD8	NULL
(	NULL
IgG2a	NULL
)	NULL
,	NULL
anti-class	NULL
II	NULL
(	NULL
H-DR-1	NULL
,	NULL
IgG2a	NULL
)	NULL
and	NULL
anti-CD4	NULL
(	NULL
IgG1	NULL
)	NULL
mAb	NULL
were	NULL
used	NULL
as	NULL
reported	NULL
previously	NULL
.	NULL

Anti-CD13	NULL
(	NULL
MCS-2	NULL
,	NULL
IgG1	NULL
)	NULL
and	NULL
anti-CD14	NULL
(	NULL
H14	NULL
,	NULL
IgG2a	NULL
)	NULL
mAb	NULL
were	NULL
used	NULL
as	NULL
isotype-matched	NULL
control	NULL
mAb	NULL
.	NULL

RESULTS	NULL
Expression	NULL
of	NULL
SART3	NULL
antigen	NULL
The	NULL
140	NULL
kD	NULL
of	NULL
the	NULL
SART3	NULL
antigen	NULL
was	NULL
expressed	NULL
in	NULL
both	NULL
the	NULL
cytosol	NULL
and	NULL
nuclear	NULL
fractions	NULL
of	NULL
all	NULL
eight	NULL
breast	NULL
cancer	NULL
cell	NULL
lines	NULL
5	NULL
o	NULL
&	NULL
o	NULL
1	NULL
7	NULL
=	NULL
g	NULL
W	NULL
u	NULL
o	NULL
Z	NULL
on	NULL
.	NULL

s	NULL
5B	NULL
dein	NULL
.	NULL

so	NULL
=	NULL
m	NULL
-	NULL
D	NULL
m-	NULL
of	NULL
E	NULL
w	NULL
m	NULL
Q	NULL
a	NULL
Q9	NULL
E	NULL
3	NULL
Q9	NULL
¥	NULL
o	NULL
5	NULL
x	NULL
oan	NULL
=	NULL
m	NULL
0	NULL
0	NULL
~	NULL
>	NULL
O	NULL
-	NULL
=	NULL
2	NULL
140	NULL
kD	NULL
--	NULL
f	NULL
»	NULL
o	NULL
o	NULL
m	NULL
m	NULL
il	NULL
Cytosol	NULL
w	NULL
in	NULL
ms	NULL
:	NULL
:	NULL
-is	NULL
II	NULL
Nucleus	NULL
Figure	NULL
1	NULL
-	NULL
Expression	NULL
of	NULL
the	NULL
SART3	NULL
antigen	NULL
in	NULL
the	NULL
breast	NULL
cancer	NULL
cell	NULL
lines	NULL
,	NULL
breast	NULL
cancer	NULL
tissue	NULL
samples	NULL
,	NULL
and	NULL
non-	NULL
tumourous	NULL
breast	NULL
tissue	NULL
samples	NULL
was	NULL
investigated	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
with	NULL
polyclonal	NULL
anti-SART3	NULL
antibody	NULL
(	NULL
Yang	NULL
et	NULL
al	NULL
,	NULL
1999	NULL
)	NULL
.	NULL

Representative	NULL
results	NULL
of	NULL
the	NULL
investigation	NULL
of	NULL
both	NULL
cytosol	NULL
and	NULL
nuclear	NULL
fractions	NULL
are	NULL
shown	NULL
.	NULL

PBMCs	NULL
of	NULL
a	NULL
healthy	NULL
donor	NULL
were	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
and	NULL
KE4	NULL
oesophageal	NULL
cancer	NULL
cells	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
.	NULL

Breast	NULL
cancer	NULL
cell	NULL
lines	NULL
included	NULL
MCF7	NULL
,	NULL
R27	NULL
,	NULL
OCUB-M	NULL
,	NULL
CRL1500	NULL
,	NULL
YMB-1-E	NULL
,	NULL
OCUB-F	NULL
,	NULL
T-47D	NULL
,	NULL
and	NULL
MDA-MB-231	NULL
.	NULL

Breast	NULL
cancer	NULL
tissues	NULL
are	NULL
shown	NULL
as	NULL
BC1	NULL
and	NULL
BC2	NULL
in	NULL
the	NULL
figure	NULL
,	NULL
while	NULL
non-tumour	NULL
breast	NULL
tissue	NULL
is	NULL
shown	NULL
as	NULL
normal	NULL
tissue	NULL
.	NULL

|	NULL
140	NULL
kD	NULL
-I	NULL
»	NULL
l	NULL
tested	NULL
.	NULL

This	NULL
band	NULL
was	NULL
also	NULL
detectable	NULL
in	NULL
the	NULL
cytosol	NULL
fraction	NULL
of	NULL
28	NULL
of	NULL
40	NULL
(	NULL
70	NULL
%	NULL
)	NULL
breast	NULL
cancer	NULL
tissue	NULL
samples	NULL
,	NULL
and	NULL
in	NULL
the	NULL
nuclear	NULL
fraction	NULL
of	NULL
30	NULL
of	NULL
40	NULL
(	NULL
75	NULL
%	NULL
)	NULL
breast	NULL
cancer	NULL
tissue	NULL
samples	NULL
.	NULL

The	NULL
bands	NULL
other	NULL
than	NULL
the	NULL
140	NULL
kD	NULL
,	NULL
which	NULL
were	NULL
observed	NULL
in	NULL
cancer	NULL
samples	NULL
,	NULL
were	NULL
evaluated	NULL
as	NULL
non-specific	NULL
since	NULL
the	NULL
polyclonal	NULL
antibody	NULL
was	NULL
used	NULL
for	NULL
the	NULL
detection	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
SART3	NULL
antigen	NULL
in	NULL
the	NULL
group	NULL
of	NULL
stage	NULL
I	NULL
and	NULL
II	NULL
was	NULL
18	NULL
of	NULL
23	NULL
samples	NULL
(	NULL
78.3	NULL
%	NULL
)	NULL
in	NULL
the	NULL
cytosol	NULL
,	NULL
and	NULL
19	NULL
of	NULL
23	NULL
samples	NULL
(	NULL
82.6	NULL
%	NULL
)	NULL
in	NULL
the	NULL
nucleus	NULL
,	NULL
while	NULL
that	NULL
in	NULL
the	NULL
group	NULL
of	NULL
the	NULL
stage	NULL
III	NULL
and	NULL
IV	NULL
was	NULL
10	NULL
of	NULL
17	NULL
samples	NULL
(	NULL
58.8	NULL
%	NULL
)	NULL
in	NULL
the	NULL
cytosol	NULL
,	NULL
and	NULL
11	NULL
of	NULL
17	NULL
samples	NULL
(	NULL
64.7	NULL
%	NULL
)	NULL
in	NULL
the	NULL
nucleus	NULL
.	NULL

However	NULL
,	NULL
it	NULL
was	NULL
not	NULL
detectable	NULL
in	NULL
either	NULL
the	NULL
cytosol	NULL
or	NULL
nuclear	NULL
fraction	NULL
of	NULL
any	NULL
of	NULL
the	NULL
normal	NULL
breast	NULL
tissue	NULL
samples	NULL
tested	NULL
.	NULL

Examples	NULL
of	NULL
results	NULL
are	NULL
shown	NULL
in	NULL
Figure	NULL
1	NULL
,	NULL
and	NULL
a	NULL
summary	NULL
of	NULL
these	NULL
results	NULL
is	NULL
presented	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

Expression	NULL
of	NULL
oestrogen	NULL
or	NULL
progesterone	NULL
receptors	NULL
The	NULL
expression	NULL
of	NULL
oestrogen	NULL
receptor	NULL
(	NULL
ER	NULL
)	NULL
or	NULL
progesterone	NULL
receptor	NULL
(	NULL
PR	NULL
)	NULL
in	NULL
these	NULL
tumours	NULL
was	NULL
investigated	NULL
in	NULL
view	NULL
of	NULL
potential	NULL
combined	NULL
immunotherapy	NULL
and	NULL
hormone	NULL
therapy	NULL
.	NULL

Twenty-three	NULL
and	NULL
17	NULL
of	NULL
the	NULL
31	NULL
breast	NULL
cancer	NULL
tumours	NULL
expressed	NULL
ER	NULL
and	NULL
PR	NULL
,	NULL
respectively	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Among	NULL
the	NULL
31	NULL
tumours	NULL
,	NULL
16	NULL
tumours	NULL
were	NULL
SART3®	NULL
and	NULL
ER*	NULL
,	NULL
two	NULL
tumours	NULL
were	NULL
SART3*	NULL
and	NULL
ER~	NULL
,	NULL
seven	NULL
tumours	NULL
were	NULL
SART3~	NULL
and	NULL
ER*	NULL
.	NULL

The	NULL
remaining	NULL
six	NULL
tumours	NULL
were	NULL
SART3~	NULL
and	NULL
ER~	NULL
.	NULL

Similarly	NULL
,	NULL
11	NULL
tumours	NULL
were	NULL
SART3*	NULL
and	NULL
PR	NULL
,	NULL
seven	NULL
tumours	NULL
were	NULL
SART3*	NULL
and	NULL
PR	NULL
,	NULL
six	NULL
tumours	NULL
were	NULL
SART3~	NULL
and	NULL
PR*	NULL
,	NULL
and	NULL
seven	NULL
tumours	NULL
were	NULL
SART3~	NULL
and	NULL
PR	NULL
.	NULL

Table	NULL
1	NULL
-	NULL
Expression	NULL
of	NULL
SART3	NULL
antigen	NULL
in	NULL
breast	NULL
cancer	NULL
Samples	NULL
Numbers	NULL
SART3	NULL
antigen	NULL
expression	NULL
Oestrogen	NULL
Progesterone	NULL
Cytosol	NULL
Nucleus	NULL
receptor	NULL
receptor	NULL
Breast	NULL
cancer	NULL
cell	NULL
lines	NULL
8	NULL
8/8	NULL
8/8	NULL
ND	NULL
ND	NULL
Stage	NULL
1	NULL
,	NULL
II	NULL
23	NULL
18/23	NULL
(	NULL
78.3	NULL
%	NULL
)	NULL
19/23	NULL
(	NULL
82.6	NULL
%	NULL
)	NULL
16/19	NULL
(	NULL
84.2	NULL
%	NULL
)	NULL
13/19	NULL
(	NULL
68.4	NULL
%	NULL
)	NULL
Breast	NULL
cancer	NULL
tissues	NULL
Stage	NULL
III	NULL
,	NULL
IV	NULL
17	NULL
10/17	NULL
(	NULL
58.8	NULL
%	NULL
)	NULL
11/17	NULL
(	NULL
64.7	NULL
%	NULL
)	NULL
8/12	NULL
(	NULL
66.7	NULL
%	NULL
)	NULL
4/12	NULL
(	NULL
33.3	NULL
%	NULL
)	NULL
Total	NULL
40	NULL
28/40	NULL
(	NULL
70.0	NULL
%	NULL
)	NULL
30/40	NULL
(	NULL
75.0	NULL
%	NULL
)	NULL
23/31	NULL
(	NULL
74.2	NULL
%	NULL
)	NULL
17/31	NULL
(	NULL
54.8	NULL
%	NULL
)	NULL
Non-tumourous	NULL
breast	NULL
tissues	NULL
3	NULL
0/3	NULL
0/3	NULL
ND	NULL
ND	NULL
ND	NULL
=	NULL
not	NULL
determined	NULL
;	NULL
percentages	NULL
of	NULL
positive	NULL
British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
2001	NULL
)	NULL
84	NULL
(	NULL
7	NULL
)	NULL
,	NULL
915-919	NULL
©2001	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
Induction	NULL
of	NULL
CTLs	NULL
by	NULL
SART3-derived	NULL
peptides	NULL
in	NULL
breast	NULL
cancer	NULL
917	NULL
A	NULL
B	NULL
SART3i00418	NULL
30	NULL
30	NULL
KE4	NULL
w	NULL
25	NULL
>	NULL
95	NULL
a	NULL
0	NULL
cj	NULL
``	NULL
20	NULL
a	NULL
ocuB-M	NULL
OCUB-M	NULL
€	NULL
2	NULL
~*~	NULL
R	NULL
§	NULL
§	NULL
!	NULL

5	NULL
15	NULL
-=-	NULL
Keda	NULL
x	NULL
a.	NULL
o.	NULL
x	NULL
m	NULL
10	NULL
10	NULL
--	NULL
R27	NULL
R27	NULL
x	NULL
5	NULL
5	NULL
-o-	NULL
VA13	NULL
o	NULL
o	NULL
VA13	NULL
5	NULL
10	NULL
20	NULL
40	NULL
5	NULL
10	NULL
20	NULL
40	NULL
0	NULL
50	NULL
100	NULL
150	NULL
200	NULL
250	NULL
25	NULL
30	NULL
R	NULL
SART3s15-328	NULL
a	NULL
20	NULL
25	NULL
a	NULL
3	NULL
20	NULL
Kea	NULL
=	NULL
g	NULL
15	NULL
a	NULL
.	NULL

-+-	NULL
OCUB-M	NULL
&	NULL
8	NULL
10	NULL
15	NULL
-=-	NULL
KE4	NULL
o©cUuB-mM	NULL
*	NULL
*	NULL
&	NULL
10	NULL
o	NULL
ho	NULL
?	NULL

R	NULL
®	NULL
5	NULL
5	NULL
-o-	NULL
VAs	NULL
o	NULL
R27	NULL
5	NULL
10	NULL
20	NULL
40	NULL
5	NULL
10	NULL
20	NULL
40	NULL
E/T	NULL
Ratio	NULL
VA13	NULL
0	NULL
100	NULL
200	NULL
300	NULL
400	NULL
C	NULL
No	NULL
Ab	NULL
anti-CD4	NULL
mAb	NULL
T	NULL
anti-CD8	NULL
mAb	NULL
E	NULL
anti-CD13	NULL
mAb	NULL
&	NULL
anti-CD14	NULL
mAb	NULL
anti-HLA	NULL
Class	NULL
I	NULL
mAb	NULL
*	NULL
anti-HLA	NULL
Class	NULL
II	NULL
mAb	NULL
0	NULL
50	NULL
100	NULL
150	NULL
200	NULL
250	NULL
INF-y	NULL
production	NULL
(	NULL
pg/ml	NULL
!	NULL
)	NULL

No	NULL
Ab	NULL
anti-CD4	NULL
mAb	NULL
N	NULL
anti-CD8	NULL
mAb	NULL
JJ	NULL
*	NULL
3	NULL
anti-CD13	NULL
mAb	NULL
&	NULL
anti-CD14	NULL
mAb	NULL
anti-HLA	NULL
Class	NULL
I	NULL
mAb	NULL
*	NULL
anti-HLA	NULL
Class	NULL
II	NULL
mAb	NULL
0	NULL
50	NULL
100	NULL
150	NULL
200	NULL
INF-y	NULL
production	NULL
(	NULL
pg/ml	NULL
!	NULL
)	NULL

Figure	NULL
2	NULL
-	NULL
CTL	NULL
activity	NULL
of	NULL
the	NULL
peptide-induced	NULL
PBMCs	NULL
.	NULL

PBMCs	NULL
stimulated	NULL
with	NULL
SART3	NULL
103.13	NULL
Or	NULL
SART3	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
peptide	NULL
were	NULL
tested	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
recognize	NULL
breast	NULL
cancer	NULL
cells	NULL
by	NULL
IFN-y	NULL
assay	NULL
(	NULL
A	NULL
)	NULL
and	NULL
6-h	NULL
``	NULL
Cr	NULL
release	NULL
assay	NULL
(	NULL
B	NULL
)	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Values	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
IFN-y	NULL
produced	NULL
from	NULL
the	NULL
peptide-stimulated	NULL
PBMCs	NULL
of	NULL
four	NULL
breast	NULL
cancer	NULL
patients	NULL
.	NULL

Background	NULL
IFN-y	NULL
production	NULL
by	NULL
the	NULL
PBMCs	NULL
alone	NULL
(	NULL
50-100	NULL
pg	NULL
ml~	NULL
'	NULL
)	NULL
has	NULL
been	NULL
subtracted	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Values	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
%	NULL
specific	NULL
lysis	NULL
of	NULL
the	NULL
triplicate	NULL
determinants	NULL
of	NULL
the	NULL
peptide-stimulated	NULL
PBMCs	NULL
of	NULL
patients	NULL
1	NULL
and	NULL
2	NULL
.	NULL

Breast	NULL
cancer	NULL
cells	NULL
used	NULL
were	NULL
OCUB-M	NULL
(	NULL
HLA-A2402	NULL
)	NULL
,	NULL
and	NULL
R27	NULL
(	NULL
HLA-A2402~	NULL
)	NULL
.	NULL

The	NULL
KE4	NULL
tumour	NULL
cell	NULL
line	NULL
was	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
,	NULL
while	NULL
VA13	NULL
cell	NULL
line	NULL
was	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

(	NULL
C	NULL
)	NULL
These	NULL
PBMCs	NULL
showing	NULL
HLA-24-restricted	NULL
CTL	NULL
activity	NULL
were	NULL
tested	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
produce	NULL
IFN-y	NULL
in	NULL
response	NULL
to	NULL
HLA-24*	NULL
breast	NULL
cancer	NULL
cells	NULL
(	NULL
OCUB-M	NULL
)	NULL
at	NULL
an	NULL
E	NULL
:	NULL
T	NULL
ratio	NULL
of	NULL
2	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
20	NULL
mg	NULL
ml-	NULL
'	NULL
of	NULL
anti-CD4	NULL
(	NULL
Nu-TH/1	NULL
)	NULL
,	NULL
anti-CD8	NULL
(	NULL
Nu-TS/C	NULL
)	NULL
,	NULL
anti-CD13	NULL
(	NULL
MCS-2	NULL
)	NULL
,	NULL
anti-CD14	NULL
(	NULL
H14	NULL
)	NULL
,	NULL
anti-class	NULL
1	NULL
(	NULL
W6/32	NULL
)	NULL
,	NULL
or	NULL
anti-class	NULL
II	NULL
(	NULL
DR	NULL
)	NULL
mAb	NULL
.	NULL

Values	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
duplicate	NULL
assays	NULL
.	NULL

The	NULL
two-tailed	NULL
Student	NULL
's	NULL
test	NULL
was	NULL
employed	NULL
for	NULL
statistical	NULL
analysis	NULL
(	NULL
*P	NULL
<	NULL
0.05	NULL
)	NULL
Induction	NULL
of	NULL
CTLs	NULL
by	NULL
the	NULL
SART3	NULL
peptides	NULL
The	NULL
SART3	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
and	NULL
SART3	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
peptides	NULL
were	NULL
tested	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
induce	NULL
CTLs	NULL
from	NULL
the	NULL
PBMCs	NULL
of	NULL
HLA-A24*	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
(	NULL
n=	NULL
4	NULL
,	NULL
histologically-determined	NULL
adenocarci-noma	NULL
)	NULL
.	NULL

These	NULL
PBMCs	NULL
produced	NULL
a	NULL
significant	NULL
level	NULL
of	NULL
IFN-y	NULL
by	NULL
recognition	NULL
of	NULL
HLA-A24*	NULL
cancer	NULL
cells	NULL
(	NULL
KE-4	NULL
and	NULL
OCUB-M	NULL
)	NULL
when	NULL
stimulated	NULL
in	NULL
vitro	NULL
with	NULL
either	NULL
SART3	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
or	NULL
SART3	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
peptide	NULL
(	NULL
Figure	NULL
2A	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
they	NULL
failed	NULL
to	NULL
react	NULL
to	NULL
HLA-A247	NULL
breast	NULL
cancer	NULL
cells	NULL
(	NULL
R27	NULL
)	NULL
.	NULL

These	NULL
effector	NULL
cells	NULL
consisted	NULL
of	NULL
20-30	NULL
%	NULL
CD3*CD4-CD8*T	NULL
cells	NULL
and	NULL
70-80	NULL
%	NULL
CD3*CD4*CD8-T	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
HLA-A24-restricted	NULL
CTL	NULL
activity	NULL
in	NULL
these	NULL
PBMCs	NULL
was	NULL
confirmed	NULL
by	NULL
a	NULL
6-h	NULL
*'Cr	NULL
release	NULL
assay	NULL
after	NULL
further	NULL
expansion	NULL
in	NULL
patients	NULL
1	NULL
and	NULL
2	NULL
.	NULL

These	NULL
peptide-stimulated	NULL
PBMCs	NULL
showed	NULL
significant	NULL
levels	NULL
of	NULL
cytotoxicity	NULL
against	NULL
the	NULL
HLA-A24*	NULL
©2001	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
tumour	NULL
cells	NULL
(	NULL
KE-4	NULL
and	NULL
OCUB-M	NULL
)	NULL
,	NULL
but	NULL
not	NULL
against	NULL
HLA-A24~	NULL
tumour	NULL
cells	NULL
(	NULL
VA13	NULL
and	NULL
R27	NULL
)	NULL
(	NULL
Figure	NULL
2B	NULL
)	NULL
.	NULL

The	NULL
CTL	NULL
activity	NULL
was	NULL
inhibited	NULL
by	NULL
anti-class	NULL
I	NULL
(	NULL
W6/32	NULL
)	NULL
or	NULL
anti-CD8	NULL
(	NULL
Nu-TS/C	NULL
)	NULL
,	NULL
but	NULL
not	NULL
by	NULL
anti-CD4	NULL
(	NULL
Nu-TH/I	NULL
)	NULL
,	NULL
anti-class	NULL
II	NULL
(	NULL
DR	NULL
)	NULL
,	NULL
anti-CD13	NULL
(	NULL
MCS-2	NULL
)	NULL
or	NULL
anti-CD14	NULL
(	NULL
H14	NULL
)	NULL
mAb	NULL
,	NULL
taken	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
(	NULL
Figure	NULL
2C	NULL
)	NULL
.	NULL

Further	NULL
,	NULL
CTL	NULL
sublines	NULL
were	NULL
established	NULL
and	NULL
tested	NULL
for	NULL
their	NULL
reactivity	NULL
to	NULL
a	NULL
peptide	NULL
in	NULL
order	NULL
to	NULL
confirm	NULL
the	NULL
peptide	NULL
specificity	NULL
in	NULL
the	NULL
CTLs	NULL
.	NULL

One	NULL
of	NULL
six	NULL
or	NULL
three	NULL
of	NULL
20	NULL
sublines	NULL
from	NULL
the	NULL
PBMCs	NULL
of	NULL
patient	NULL
1	NULL
,	NULL
when	NULL
stimulated	NULL
with	NULL
the	NULL
SART3	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
peptide	NULL
or	NULL
SART3	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
peptide	NULL
,	NULL
produced	NULL
a	NULL
significant	NULL
amount	NULL
of	NULL
IFN-y	NULL
by	NULL
recognition	NULL
of	NULL
C1R-A2402	NULL
cells	NULL
pulsed	NULL
with	NULL
a	NULL
corresponding	NULL
peptide	NULL
,	NULL
respectively	NULL
(	NULL
Figure	NULL
3A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
one	NULL
of	NULL
three	NULL
or	NULL
four	NULL
of	NULL
20	NULL
sublines	NULL
from	NULL
PBMCs	NULL
of	NULL
patient	NULL
2	NULL
,	NULL
when	NULL
stimulated	NULL
with	NULL
the	NULL
SART3	NULL
,	NULL
,	NULL
,	NULL
,	NULL
peptide	NULL
or	NULL
SART3	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
peptide	NULL
,	NULL
produced	NULL
a	NULL
significant	NULL
British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
2001	NULL
)	NULL
84	NULL
(	NULL
7	NULL
)	NULL
,	NULL
915-919	NULL
918	NULL
Y	NULL
Suefuji	NULL
et	NULL
al	NULL
A	NULL
SART3100-118	NULL
No	NULL
peptide	NULL
SART3	NULL
100-118	NULL
x	NULL
Patient	NULL
1	NULL
SART3	NULL
HIVenv	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
INF-y	NULL
production	NULL
(	NULL
pg	NULL
ml~	NULL
'	NULL
)	NULL
C	NULL
SART3100-118	NULL
No	NULL
peptide	NULL
SART3	NULL
100-118	NULL
*	NULL
Patient	NULL
2	NULL
SART3	NULL
HIVenv	NULL
=	NULL
]	NULL
20	NULL
40	NULL
60	NULL
INF-y	NULL
production	NULL
(	NULL
pg	NULL
ml~	NULL
!	NULL
)	NULL

Figure	NULL
3	NULL
-	NULL
Peptide	NULL
specificity	NULL
of	NULL
CTL	NULL
sublines	NULL
was	NULL
established	NULL
by	NULL
incubation	NULL
of	NULL
the	NULL
PBMCs	NULL
of	NULL
patients	NULL
1	NULL
and	NULL
2	NULL
,	NULL
which	NULL
had	NULL
been	NULL
stimulated	NULL
with	NULL
the	NULL
SART3	NULL
B	NULL
SART3315.323	NULL
No	NULL
peptide	NULL
T	NULL
SART3	NULL
100-118	NULL
3	NULL
&	NULL
SART3	NULL
*	NULL
HIVenv	NULL
0	NULL
50	NULL
100	NULL
150	NULL
INF-y	NULL
production	NULL
(	NULL
pg	NULL
ml~	NULL
'	NULL
)	NULL
D	NULL
SART3315.923	NULL
No	NULL
peptide	NULL
SART3	NULL
100118	NULL
Patient	NULL
2	NULL
SART3	NULL
315.323	NULL
x	NULL
HIVenv	NULL
0	NULL
20	NULL
40	NULL
60	NULL
80	NULL
100	NULL
INF-y	NULL
production	NULL
(	NULL
pg	NULL
ml-	NULL
'	NULL
)	NULL
108-118	NULL
or	NULL
SART3	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
peptide	NULL
.	NULL

HLA-A2402-binding	NULL
HIV	NULL
peptide	NULL
(	NULL
RYLRDQQLLGI	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

One	NULL
of	NULL
six	NULL
or	NULL
three	NULL
of	NULL
20	NULL
sublines	NULL
from	NULL
the	NULL
PBMCs	NULL
of	NULL
patient	NULL
1	NULL
,	NULL
when	NULL
stimulated	NULL
with	NULL
the	NULL
SART3	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
peptide	NULL
or	NULL
SART3	NULL
,	NULL
,	NULL
,	NULL
,	NULL
.	NULL

,	NULL
,	NULL
peptide	NULL
,	NULL
produced	NULL
a	NULL
significant	NULL
amount	NULL
of	NULL
IFN-y	NULL
by	NULL
recognition	NULL
of	NULL
C1R-A2402	NULL
cells	NULL
pulsed	NULL
with	NULL
a	NULL
corresponding	NULL
peptide	NULL
,	NULL
respectively	NULL
(	NULL
A	NULL
,	NULL
B	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
one	NULL
of	NULL
three	NULL
or	NULL
four	NULL
of	NULL
20	NULL
sublines	NULL
from	NULL
the	NULL
PBMCs	NULL
of	NULL
patient	NULL
2	NULL
,	NULL
when	NULL
stimulated	NULL
with	NULL
the	NULL
SART3	NULL
,	NULL
peptide	NULL
or	NULL
SART	NULL
3	NULL
,	NULL
peptide	NULL
,	NULL
produced	NULL
a	NULL
significant	NULL
amount	NULL
of	NULL
IFN-y	NULL
by	NULL
recognition	NULL
of	NULL
C1R-A2402	NULL
cells	NULL
pulsed	NULL
with	NULL
a	NULL
corresponding	NULL
peptide	NULL
,	NULL
respectively	NULL
(	NULL
C	NULL
,	NULL
D	NULL
)	NULL
.	NULL

The	NULL
other	NULL
sublines	NULL
failed	NULL
to	NULL
show	NULL
peptide	NULL
specificity	NULL
.	NULL

Values	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
duplicate	NULL
assays	NULL
.	NULL

The	NULL
two-tailed	NULL
Student	NULL
's	NULL
test	NULL
was	NULL
employed	NULL
for	NULL
statistical	NULL
analysis	NULL
(	NULL
*P	NULL
<	NULL
0.05	NULL
)	NULL
amount	NULL
of	NULL
IFN-y	NULL
by	NULL
recognition	NULL
of	NULL
C1R-A2402	NULL
cells	NULL
pulsed	NULL
with	NULL
a	NULL
corresponding	NULL
peptide	NULL
,	NULL
respectively	NULL
(	NULL
Figure	NULL
3C	NULL
,	NULL
D	NULL
)	NULL
.	NULL

DISCUSSION	NULL
This	NULL
study	NULL
showed	NULL
that	NULL
the	NULL
SART3	NULL
antigen	NULL
encoding	NULL
tumour	NULL
epitopes	NULL
capable	NULL
of	NULL
inducing	NULL
CTLs	NULL
was	NULL
expressed	NULL
in	NULL
both	NULL
the	NULL
cytosol	NULL
and	NULL
nuclear	NULL
fractions	NULL
of	NULL
all	NULL
breast	NULL
cell	NULL
lines	NULL
and	NULL
the	NULL
majority	NULL
of	NULL
breast	NULL
tumours	NULL
tested	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
this	NULL
antigen	NULL
was	NULL
undetectable	NULL
in	NULL
non-tumourous	NULL
breast	NULL
tissue	NULL
samples	NULL
.	NULL

We	NULL
recently	NULL
obtained	NULL
evidence	NULL
that	NULL
this	NULL
is	NULL
a	NULL
RNA-binding	NULL
protein	NULL
involved	NULL
in	NULL
splicing	NULL
regulation	NULL
of	NULL
RNA	NULL
(	NULL
Harada	NULL
,	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
SART3	NULL
antigen	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
cellular	NULL
proliferation	NULL
.	NULL

This	NULL
issue	NULL
is	NULL
now	NULL
under	NULL
investigation	NULL
in	NULL
our	NULL
laboratory	NULL
.	NULL

The	NULL
present	NULL
study	NULL
also	NULL
showed	NULL
that	NULL
the	NULL
SART3	NULL
;	NULL
,	NULL
,	NULL
;	NULL
,	NULL
,	NULL
and	NULL
SART	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
peptide	NULL
induced	NULL
HLA-A24-restricted	NULL
CTLs	NULL
recognizing	NULL
the	NULL
SART3*	NULL
tumour	NULL
cells	NULL
including	NULL
breast	NULL
cancer	NULL
cells	NULL
in	NULL
the	NULL
PBMCs	NULL
of	NULL
all	NULL
HLA-A24*	NULL
breast	NULL
cancer	NULL
patients	NULL
tested	NULL
.	NULL

These	NULL
CTLs	NULL
failed	NULL
to	NULL
lyse	NULL
either	NULL
HLA-A247	NULL
tumour	NULL
cells	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
or	NULL
HLA-A24*	NULL
normal	NULL
T	NULL
cells	NULL
(	NULL
PHA-blastic	NULL
cells	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
the	NULL
presence	NULL
of	NULL
CTL	NULL
precursors	NULL
reacting	NULL
to	NULL
the	NULL
SART3	NULL
epitope	NULL
on	NULL
breast	NULL
cancer	NULL
cells	NULL
in	NULL
the	NULL
circulation	NULL
of	NULL
the	NULL
majority	NULL
of	NULL
breast	NULL
cancer	NULL
patients	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
SART3	NULL
antigen	NULL
,	NULL
the	NULL
other	NULL
tumour	NULL
antigens	NULL
(	NULL
MAGE-1	NULL
,	NULL
MAGE-4	NULL
,	NULL
SARTL	NULL
,	NULL
,	NULL
,	NULL
MUC1	NULL
)	NULL
were	NULL
expressed	NULL
in	NULL
only	NULL
a	NULL
portion	NULL
of	NULL
breast	NULL
cancers	NULL
(	NULL
Vincenzo	NULL
et	NULL
al	NULL
,	NULL
1995	NULL
;	NULL
Reddish	NULL
et	NULL
al	NULL
,	NULL
1998	NULL
;	NULL
Kawamoto	NULL
et	NULL
al	NULL
,	NULL
1999	NULL
)	NULL
.	NULL

Further	NULL
,	NULL
no	NULL
peptides	NULL
were	NULL
proven	NULL
to	NULL
have	NULL
the	NULL
ability	NULL
to	NULL
induce	NULL
HLA-class	NULL
I	NULL
restricted	NULL
CTLs	NULL
reacting	NULL
to	NULL
breast	NULL
cancer	NULL
cells	NULL
.	NULL

Administration	NULL
of	NULL
HER2/neu	NULL
peptide	NULL
capable	NULL
of	NULL
binding	NULL
to	NULL
HLA-A2	NULL
molecules	NULL
failed	NULL
to	NULL
induce	NULL
the	NULL
CTL	NULL
activity	NULL
British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
2001	NULL
)	NULL
84	NULL
(	NULL
7	NULL
)	NULL
,	NULL
915-919	NULL
against	NULL
cancer	NULL
cells	NULL
(	NULL
Zaks	NULL
and	NULL
Rosenberg	NULL
,	NULL
1998	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
SART3	NULL
antigen	NULL
and	NULL
its	NULL
peptides	NULL
could	NULL
be	NULL
one	NULL
of	NULL
the	NULL
most	NULL
appropriate	NULL
molecules	NULL
for	NULL
use	NULL
in	NULL
specific	NULL
immunotherapy	NULL
of	NULL
breast	NULL
cancer	NULL
patients	NULL
.	NULL

There	NULL
are	NULL
few	NULL
treatment	NULL
modalities	NULL
available	NULL
for	NULL
patients	NULL
with	NULL
breast	NULL
cancer	NULL
which	NULL
is	NULL
lacking	NULL
ER	NULL
or	NULL
resistant	NULL
to	NULL
the	NULL
existing	NULL
hormone	NULL
therapy	NULL
(	NULL
Slamon	NULL
et	NULL
al	NULL
,	NULL
1989	NULL
;	NULL
Teixeira	NULL
et	NULL
al	NULL
,	NULL
1995	NULL
;	NULL
Yamauchi	NULL
et	NULL
al	NULL
,	NULL
1997	NULL
)	NULL
.	NULL

Among	NULL
31	NULL
tumours	NULL
tested	NULL
,	NULL
16	NULL
(	NULL
52	NULL
%	NULL
)	NULL
expressed	NULL
both	NULL
SART3	NULL
and	NULL
ER	NULL
,	NULL
two	NULL
(	NULL
7	NULL
%	NULL
)	NULL
were	NULL
SART3*	NULL
and	NULL
ER	NULL
,	NULL
seven	NULL
(	NULL
23	NULL
%	NULL
)	NULL
were	NULL
SART3~	NULL
and	NULL
ER	NULL
*	NULL
,	NULL
and	NULL
six	NULL
(	NULL
19	NULL
%	NULL
)	NULL
were	NULL
SART3~	NULL
and	NULL
ER~	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
a	NULL
substantial	NULL
proportion	NULL
of	NULL
breast	NULL
cancer	NULL
patients	NULL
would	NULL
be	NULL
appropriate	NULL
candidates	NULL
for	NULL
specific	NULL
immunotherapy	NULL
with	NULL
the	NULL
SART3	NULL
peptides	NULL
,	NULL
either	NULL
administered	NULL
independently	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
hormone	NULL
therapy	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
PR	NULL
.	NULL

Further	NULL
,	NULL
SART3	NULL
expression	NULL
in	NULL
the	NULL
group	NULL
of	NULL
stage	NULL
I	NULL
and	NULL
II	NULL
was	NULL
higher	NULL
than	NULL
that	NULL
in	NULL
the	NULL
group	NULL
of	NULL
stage	NULL
III	NULL
and	NULL
IV	NULL
.	NULL

A	NULL
similar	NULL
trend	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
ER	NULL
and	NULL
PR	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
both	NULL
immunotherapy	NULL
and	NULL
hormone	NULL
therapy	NULL
are	NULL
more	NULL
effective	NULL
for	NULL
breast	NULL
cancer	NULL
patients	NULL
with	NULL
early	NULL
stage	NULL
rather	NULL
than	NULL
the	NULL
patients	NULL
with	NULL
advanced	NULL
stage	NULL
,	NULL
although	NULL
details	NULL
involved	NULL
in	NULL
this	NULL
phenomenon	NULL
is	NULL
not	NULL
clear	NULL
at	NULL
the	NULL
present	NULL
time	NULL
.	NULL

The	NULL
HLA-A24	NULL
allele	NULL
is	NULL
found	NULL
in	NULL
60	NULL
%	NULL
of	NULL
Japanese	NULL
,	NULL
20	NULL
%	NULL
of	NULL
Caucasians	NULL
and	NULL
12	NULL
%	NULL
of	NULL
Africans	NULL
(	NULL
Imanishi	NULL
et	NULL
al	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
identified	NULL
tumour-epitopes	NULL
of	NULL
the	NULL
SART3	NULL
antigen	NULL
on	NULL
HLA-A0207	NULL
molecules	NULL
,	NULL
which	NULL
are	NULL
able	NULL
to	NULL
induce	NULL
HLA-A2-restricted	NULL
and	NULL
tumour-specific	NULL
CTLs	NULL
in	NULL
the	NULL
PBMCs	NULL
of	NULL
epithelial	NULL
cancer	NULL
patients	NULL
(	NULL
Ito	NULL
et	NULL
al	NULL
,	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

The	NULL
HLA-A2	NULL
allele	NULL
is	NULL
found	NULL
in	NULL
40	NULL
%	NULL
of	NULL
Japanese	NULL
,	NULL
50	NULL
%	NULL
of	NULL
Caucasians	NULL
and	NULL
12	NULL
%	NULL
of	NULL
Africans	NULL
(	NULL
Imanishi	NULL
et	NULL
al	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

©2001	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
Subsequently	NULL
,	NULL
the	NULL
SART3	NULL
antigen	NULL
and	NULL
its	NULL
peptides	NULL
could	NULL
be	NULL
an	NULL
appropriate	NULL
molecule	NULL
for	NULL
use	NULL
in	NULL
specific	NULL
immunotherapy	NULL
of	NULL
HLA-A24*	NULL
or	NULL
-A2*	NULL
breast	NULL
cancer	NULL
patients	NULL
.	NULL

These	NULL
findings	NULL
could	NULL
provide	NULL
important	NULL
information	NULL
for	NULL
the	NULL
development	NULL
of	NULL
a	NULL
specific	NULL
immunotherapy	NULL
for	NULL
a	NULL
relatively	NULL
large	NULL
number	NULL
of	NULL
breast	NULL
cancer	NULL
patients	NULL
all	NULL
over	NULL
the	NULL
world	NULL
.	NULL

ACKNOWLEDGEMENTS	NULL
We	NULL
thank	NULL
Dr	NULL
Kunzo	NULL
Orita	NULL
,	NULL
an	NULL
Executive	NULL
Director	NULL
of	NULL
Hayashibara	NULL
Biochemical	NULL
Lab	NULL
Inc	NULL
,	NULL
Japan	NULL
,	NULL
for	NULL
providing	NULL
the	NULL
natural	NULL
human	NULL
IFN-y	NULL
with	NULL
which	NULL
to	NULL
develop	NULL
an	NULL
IFN-y	NULL
ELISA	NULL
system	NULL
.	NULL

This	NULL
study	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
Grants-in-Aid	NULL
from	NULL
the	NULL
Ministry	NULL
of	NULL
Education	NULL
,	NULL
Science	NULL
,	NULL
Sports	NULL
,	NULL
and	NULL
Culture	NULL
of	NULL
Japan	NULL
(	NULL
08266266	NULL
)	NULL
,	NULL
and	NULL
from	NULL
the	NULL
Ministry	NULL
of	NULL
Health	NULL
and	NULL
Welfare	NULL
,	NULL
Japan	NULL
(	NULL
H10-genome-003	NULL
)	NULL
.	NULL

REFERENCES	NULL
David	NULL
CL	NULL
,	NULL
Peter	NULL
SG	NULL
,	NULL
George	NULL
EP	NULL
,	NULL
Selwyn	NULL
OR	NULL
and	NULL
Timothy	NULL
JE	NULL
(	NULL
1995	NULL
)	NULL
Tumor-specific	NULL
and	NULL
HLA-A2-restricted	NULL
cytolysis	NULL
tumor-associated	NULL
lymphocytes	NULL
in	NULL
human	NULL
metastatic	NULL
breast	NULL
cancer	NULL
.	NULL

J	NULL
Immunol	NULL
155	NULL
;	NULL
4486-4491	NULL
Gaugler	NULL
B	NULL
,	NULL
van	NULL
den	NULL
Eynde	NULL
B	NULL
,	NULL
van	NULL
der	NULL
Bruggen	NULL
P	NULL
,	NULL
Romero	NULL
P	NULL
,	NULL
Gaforio	NULL
JJ	NULL
,	NULL
de	NULL
Plaen	NULL
E	NULL
,	NULL
Lethe	NULL
B	NULL
,	NULL
Brasseur	NULL
F	NULL
and	NULL
Boon	NULL
T	NULL
(	NULL
1994	NULL
)	NULL
Human	NULL
gene	NULL
MAGE-3	NULL
codes	NULL
for	NULL
an	NULL
antigen	NULL
recognized	NULL
on	NULL
a	NULL
melanoma	NULL
by	NULL
autologous	NULL
cytolytic	NULL
T	NULL
lymphocytes	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
179	NULL
:	NULL
921-930	NULL
Imanishi	NULL
T	NULL
,	NULL
Akazawa	NULL
T	NULL
,	NULL
Kimura	NULL
A	NULL
,	NULL
Tokunaga	NULL
K	NULL
and	NULL
Gojobori	NULL
T	NULL
(	NULL
1992	NULL
)	NULL
Allele	NULL
and	NULL
haplotype	NULL
frequencies	NULL
for	NULL
HLA	NULL
and	NULL
complement	NULL
loci	NULL
in	NULL
various	NULL
ethnic	NULL
groups	NULL
.	NULL

In	NULL
:	NULL
HLA	NULL
1991	NULL
,	NULL
Vol	NULL
.	NULL

1	NULL
.	NULL

Tsuji	NULL
K	NULL
,	NULL
Aizawa	NULL
M	NULL
and	NULL
Sasazuki	NULL
(	NULL
eds	NULL
)	NULL
pp	NULL
1065-1220	NULL
.	NULL

Oxford	NULL
Scientific	NULL
Publications	NULL
,	NULL
Oxford	NULL
Inoue	NULL
H	NULL
,	NULL
Mori	NULL
M	NULL
,	NULL
Honda	NULL
M	NULL
,	NULL
Li	NULL
J	NULL
,	NULL
Shibata	NULL
K	NULL
,	NULL
Mimori	NULL
K	NULL
,	NULL
Ueo	NULL
H	NULL
and	NULL
Akiyoshi	NULL
T	NULL
(	NULL
1995	NULL
)	NULL
The	NULL
expression	NULL
of	NULL
tumor-rejection	NULL
antigens	NULL
of	NULL
MAGE	NULL
genes	NULL
.	NULL

Int	NULL
J	NULL
Cancer	NULL
62	NULL
;	NULL
523-526	NULL
Kawakami	NULL
Y	NULL
,	NULL
Eliyahu	NULL
S	NULL
,	NULL
Sakaguchi	NULL
K	NULL
,	NULL
Robbins	NULL
PF	NULL
,	NULL
Rivoltini	NULL
L	NULL
,	NULL
Yannelli	NULL
JR	NULL
,	NULL
Appella	NULL
E	NULL
and	NULL
Rosenberg	NULL
SA	NULL
(	NULL
1994	NULL
)	NULL
Identification	NULL
of	NULL
the	NULL
immunodominant	NULL
peptides	NULL
of	NULL
the	NULL
MART-1	NULL
human	NULL
melanoma	NULL
antigen	NULL
recognized	NULL
by	NULL
the	NULL
majority	NULL
of	NULL
HLA-A2-restricted	NULL
tumor	NULL
infiltrating	NULL
lymphocytes	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
180	NULL
:	NULL
347-352	NULL
Kawakami	NULL
Y	NULL
,	NULL
Eliyahu	NULL
S	NULL
,	NULL
Jennings	NULL
C	NULL
,	NULL
Sakaguchi	NULL
K	NULL
,	NULL
Kang	NULL
X	NULL
,	NULL
Southwood	NULL
S	NULL
,	NULL
Robbins	NULL
PF	NULL
,	NULL
Sette	NULL
A	NULL
,	NULL
Appella	NULL
E	NULL
and	NULL
Rosenberg	NULL
SA	NULL
(	NULL
1995	NULL
)	NULL
Recognition	NULL
of	NULL
multiple	NULL
epitopes	NULL
in	NULL
the	NULL
human	NULL
melanoma	NULL
antigen	NULL
gp100	NULL
by	NULL
tumor-infiltrating	NULL
T	NULL
lymphocytes	NULL
associated	NULL
with	NULL
in	NULL
vivo	NULL
tumor	NULL
regression	NULL
.	NULL

J	NULL
Immunol	NULL
154	NULL
:	NULL
3961-3968	NULL
Kawamoto	NULL
M	NULL
,	NULL
Shichijo	NULL
S	NULL
,	NULL
Imai	NULL
Y	NULL
and	NULL
Itoh	NULL
K	NULL
(	NULL
1999	NULL
)	NULL
Expression	NULL
of	NULL
the	NULL
SART1	NULL
tumor	NULL
rejection	NULL
antigen	NULL
in	NULL
breast	NULL
cancer	NULL
.	NULL

Int	NULL
J	NULL
Cancer	NULL
80	NULL
:	NULL
64-67	NULL
Kikuchi	NULL
M	NULL
,	NULL
Nakao	NULL
M	NULL
,	NULL
Inoue	NULL
Y	NULL
,	NULL
Matsunaga	NULL
K	NULL
,	NULL
Shichijo	NULL
S	NULL
,	NULL
Yamana	NULL
H	NULL
and	NULL
Itoh	NULL
K	NULL
(	NULL
1999	NULL
)	NULL
Identification	NULL
of	NULL
a	NULL
SART1-derived	NULL
peptide	NULL
capable	NULL
of	NULL
inducing	NULL
HLA-A24-restricted	NULL
and	NULL
tumor-specific	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

Int	NULL
J	NULL
Cancer	NULL
81	NULL
459-466	NULL
Marchand	NULL
M	NULL
,	NULL
van	NULL
Baren	NULL
N	NULL
,	NULL
Weynants	NULL
P	NULL
,	NULL
Brichard	NULL
V	NULL
,	NULL
Dreno	NULL
B	NULL
,	NULL
Tessier	NULL
MH	NULL
,	NULL
Rankin	NULL
E	NULL
,	NULL
Parmiani	NULL
G	NULL
,	NULL
Arienti	NULL
F	NULL
,	NULL
Humblet	NULL
Y	NULL
,	NULL
Bourlond	NULL
A	NULL
,	NULL
Vanwijck	NULL
R	NULL
,	NULL
Lienard	NULL
D	NULL
,	NULL
©2001	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
Induction	NULL
of	NULL
CTLs	NULL
by	NULL
SART3-derived	NULL
peptides	NULL
in	NULL
breast	NULL
cancer	NULL
919	NULL
Beauduin	NULL
M	NULL
,	NULL
Dietrich	NULL
PY	NULL
,	NULL
Russo	NULL
V	NULL
,	NULL
Kerger	NULL
J	NULL
,	NULL
Masucci	NULL
G	NULL
,	NULL
Jager	NULL
E	NULL
,	NULL
de	NULL
Greve	NULL
J	NULL
,	NULL
Atzpodien	NULL
J	NULL
,	NULL
Brasseur	NULL
F	NULL
,	NULL
Coulie	NULL
PG	NULL
,	NULL
van	NULL
der	NULL
Bruggen	NULL
P	NULL
and	NULL
Boon	NULL
T	NULL
(	NULL
1999	NULL
)	NULL
Tumor	NULL
regressions	NULL
observed	NULL
in	NULL
patients	NULL
with	NULL
metastatic	NULL
melanoma	NULL
treated	NULL
with	NULL
an	NULL
antigenic	NULL
peptide	NULL
encoded	NULL
by	NULL
gene	NULL
MAGE-3	NULL
and	NULL
presented	NULL
by	NULL
HLA-A1	NULL
.	NULL

Int	NULL
J	NULL
Cancer	NULL
80	NULL
:	NULL
219-230	NULL
Murayama	NULL
K	NULL
,	NULL
Kogayashi	NULL
T	NULL
,	NULL
Imaizumi	NULL
T	NULL
,	NULL
Matsunaga	NULL
K	NULL
,	NULL
Kuramoto	NULL
T	NULL
,	NULL
Shigemori	NULL
M	NULL
,	NULL
Shichijo	NULL
S	NULL
and	NULL
Itoh	NULL
K	NULL
(	NULL
2000	NULL
)	NULL
Expression	NULL
of	NULL
the	NULL
SART3	NULL
tumor-rejection	NULL
antigen	NULL
in	NULL
brain	NULL
tumors	NULL
and	NULL
induction	NULL
of	NULL
cytotoxic	NULL
T	NULL
lymphocyres	NULL
by	NULL
its	NULL
peptide	NULL
.	NULL

J	NULL
Immunotherapy	NULL
23	NULL
(	NULL
5	NULL
)	NULL
511-518	NULL
Nestle	NULL
FO	NULL
,	NULL
Alijagic	NULL
S	NULL
,	NULL
Gilliet	NULL
M	NULL
,	NULL
Sun	NULL
Y	NULL
,	NULL
Grabbe	NULL
S	NULL
,	NULL
Dummer	NULL
R	NULL
,	NULL
Burg	NULL
G	NULL
and	NULL
Schadendorf	NULL
D	NULL
(	NULL
1998	NULL
)	NULL
Vaccination	NULL
of	NULL
melanoma	NULL
patients	NULL
with	NULL
peptide-	NULL
or	NULL
tumor	NULL
lysate-pulsed	NULL
dendritic	NULL
cells	NULL
.	NULL

Nature	NULL
Med	NULL
4	NULL
:	NULL
328-332	NULL
Robbins	NULL
PF	NULL
,	NULL
El-gamil	NULL
M	NULL
,	NULL
Li	NULL
YF	NULL
,	NULL
Kawakami	NULL
Y	NULL
,	NULL
Loftus	NULL
D	NULL
,	NULL
Appella	NULL
E	NULL
and	NULL
Rosenberg	NULL
SA	NULL
(	NULL
1996	NULL
)	NULL
A	NULL
mutated	NULL
B-catenin	NULL
gene	NULL
encodes	NULL
a	NULL
melanoma-specific	NULL
antigen	NULL
recognized	NULL
by	NULL
tumor	NULL
infiltrating	NULL
lymphocytes	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
183	NULL
:	NULL
1185-1192	NULL
Robbins	NULL
PF	NULL
,	NULL
El-gamil	NULL
M	NULL
,	NULL
Li	NULL
YF	NULL
,	NULL
Fitzgerald	NULL
EB	NULL
,	NULL
Kawakami	NULL
Y	NULL
and	NULL
Rosenberg	NULL
SA	NULL
(	NULL
1997	NULL
)	NULL
The	NULL
intronic	NULL
region	NULL
of	NULL
an	NULL
incompletely	NULL
spliced	NULL
gp	NULL
100	NULL
gene	NULL
transcript	NULL
encodes	NULL
an	NULL
epitope	NULL
recognized	NULL
by	NULL
melanoma-reactive	NULL
tumor-infiltrating	NULL
lymphocytes	NULL
.	NULL

J	NULL
Immunol	NULL
159	NULL
:	NULL
303-308	NULL
Rosenberg	NULL
SA	NULL
,	NULL
Yang	NULL
JC	NULL
,	NULL
Schwartzentruber	NULL
DJ	NULL
,	NULL
Hwu	NULL
P	NULL
,	NULL
Marincola	NULL
FM	NULL
,	NULL
Topalian	NULL
SL	NULL
,	NULL
Restifo	NULL
NP	NULL
,	NULL
Dudley	NULL
ME	NULL
,	NULL
Schwarz	NULL
SL	NULL
,	NULL
Spiess	NULL
PJ	NULL
,	NULL
Wunderlich	NULL
JR	NULL
,	NULL
Parkhurst	NULL
MR	NULL
,	NULL
Kawakami	NULL
Y	NULL
,	NULL
Seipp	NULL
CA	NULL
,	NULL
Einhorn	NULL
JH	NULL
and	NULL
White	NULL
DE	NULL
(	NULL
1998	NULL
)	NULL
Immunologic	NULL
and	NULL
therapeutic	NULL
evaluation	NULL
of	NULL
a	NULL
synthetic	NULL
peptide	NULL
vaccine	NULL
for	NULL
the	NULL
treatment	NULL
of	NULL
patients	NULL
with	NULL
metastatic	NULL
melanoma	NULL
.	NULL

Nature	NULL
Med	NULL
4	NULL
:	NULL
321-327	NULL
Slamon	NULL
DJ	NULL
,	NULL
Godolphin	NULL
W	NULL
,	NULL
Jones	NULL
LA	NULL
,	NULL
Holt	NULL
JA	NULL
,	NULL
Wong	NULL
SG	NULL
,	NULL
Keith	NULL
DE	NULL
,	NULL
Levin	NULL
WJ	NULL
,	NULL
Stuart	NULL
SG	NULL
,	NULL
Udove	NULL
J	NULL
,	NULL
Ullrich	NULL
A	NULL
and	NULL
Press	NULL
MF	NULL
(	NULL
1989	NULL
)	NULL
Studies	NULL
of	NULL
the	NULL
HER-2/neu	NULL
proto-oncogene	NULL
in	NULL
human	NULL
breast	NULL
and	NULL
ovarian	NULL
cancer	NULL
.	NULL

Science	NULL
244	NULL
:	NULL
707-712	NULL
Traverrsari	NULL
C	NULL
,	NULL
Meazza	NULL
R	NULL
,	NULL
Coppolecchia	NULL
M	NULL
,	NULL
Basso	NULL
S	NULL
,	NULL
Verrecchia	NULL
A	NULL
,	NULL
van	NULL
der	NULL
Bruggen	NULL
P	NULL
,	NULL
Ardizzoni	NULL
A	NULL
,	NULL
Gsggero	NULL
A	NULL
and	NULL
Ferrini	NULL
S	NULL
(	NULL
1997	NULL
)	NULL
IFN-y	NULL
gene	NULL
transfer	NULL
restores	NULL
HLA-class	NULL
I	NULL
expression	NULL
and	NULL
MAGE-3	NULL
antigen	NULL
presentation	NULL
to	NULL
CTL	NULL
in	NULL
HLA-deficient	NULL
small	NULL
cell	NULL
lung	NULL
cancer	NULL
.	NULL

Gene	NULL
Therapy	NULL
4	NULL
:	NULL
1029-1035	NULL
van	NULL
der	NULL
Bruggen	NULL
P	NULL
,	NULL
Traversari	NULL
C	NULL
,	NULL
Chomes	NULL
P	NULL
,	NULL
Lurquin	NULL
C	NULL
,	NULL
de	NULL
Plaen	NULL
E	NULL
,	NULL
van	NULL
den	NULL
Eynde	NULL
B	NULL
,	NULL
Knuth	NULL
A	NULL
and	NULL
Boon	NULL
T	NULL
(	NULL
1991	NULL
)	NULL
A	NULL
gene	NULL
encoding	NULL
an	NULL
antigen	NULL
recognized	NULL
by	NULL
cytolytic	NULL
T	NULL
lymphocytes	NULL
on	NULL
a	NULL
human	NULL
melanoma	NULL
.	NULL

Science	NULL
254	NULL
:	NULL
1643-1647	NULL
van	NULL
der	NULL
Bruggen	NULL
P	NULL
,	NULL
Bastin	NULL
J	NULL
,	NULL
Gajewski	NULL
T	NULL
,	NULL
Coulie	NULL
PG	NULL
,	NULL
Boul	NULL
P	NULL
,	NULL
de	NULL
Smet	NULL
C	NULL
,	NULL
Traversari	NULL
C	NULL
,	NULL
Townsent	NULL
A	NULL
and	NULL
Boon	NULL
T	NULL
(	NULL
1994	NULL
)	NULL
A	NULL
peptide	NULL
encoded	NULL
by	NULL
human	NULL
gene	NULL
MAGE-3	NULL
and	NULL
presented	NULL
by	NULL
HLA-A2	NULL
induces	NULL
cytolytic	NULL
T	NULL
lymphocytes	NULL
that	NULL
recognize	NULL
tumor	NULL
cells	NULL
expressing	NULL
MAGE-3	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
24	NULL
:	NULL
3038-3043	NULL
Vasso	NULL
A	NULL
,	NULL
Vaios	NULL
K	NULL
,	NULL
John	NULL
SH	NULL
and	NULL
Ian	NULL
FCM	NULL
(	NULL
1997	NULL
)	NULL
Induction	NULL
of	NULL
HLA-A2-restricted	NULL
CTLs	NULL
to	NULL
the	NULL
mucin	NULL
1	NULL
human	NULL
breast	NULL
cancer	NULL
antigen	NULL
.	NULL

J	NULL
Immuno	NULL
!	NULL

159	NULL
:	NULL
5211-5218	NULL
Vincenzo	NULL
R	NULL
,	NULL
Catia	NULL
T	NULL
,	NULL
Alessandro	NULL
V	NULL
,	NULL
Marccella	NULL
M	NULL
,	NULL
Pier	NULL
N	NULL
and	NULL
Claudio	NULL
B	NULL
(	NULL
1995	NULL
)	NULL
Expression	NULL
of	NULL
the	NULL
MAGE	NULL
gene	NULL
family	NULL
and	NULL
metastatic	NULL
human	NULL
breast	NULL
cancer	NULL
:	NULL
implication	NULL
for	NULL
tumor	NULL
antigen-specific	NULL
immunotherapy	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
64	NULL
:	NULL
216-221	NULL
Yamauchi	NULL
H	NULL
,	NULL
O'neill	NULL
A	NULL
,	NULL
Gelman	NULL
R	NULL
,	NULL
Carney	NULL
W	NULL
,	NULL
Tenney	NULL
DY	NULL
,	NULL
Hosch	NULL
S	NULL
and	NULL
Hayes	NULL
DF	NULL
(	NULL
1997	NULL
)	NULL
Prediction	NULL
of	NULL
response	NULL
to	NULL
antiestrogen	NULL
therapy	NULL
in	NULL
advanced	NULL
breast	NULL
cancer	NULL
patients	NULL
by	NULL
pretreatment	NULL
circulating	NULL
levels	NULL
of	NULL
extracellular	NULL
domain	NULL
of	NULL
the	NULL
HER-2/c-neu	NULL
protein	NULL
.	NULL

J	NULL
Clin	NULL
Oncol	NULL
15	NULL
:	NULL
2518-2525	NULL
Yang	NULL
D	NULL
,	NULL
Nakao	NULL
M	NULL
,	NULL
Shichijo	NULL
S	NULL
,	NULL
Sasatomi	NULL
T	NULL
,	NULL
Takatu	NULL
H	NULL
,	NULL
Matsumoto	NULL
H	NULL
,	NULL
Mori	NULL
K	NULL
,	NULL
Yamana	NULL
H	NULL
,	NULL
Shirouzu	NULL
K	NULL
and	NULL
Itoh	NULL
K	NULL
(	NULL
1999	NULL
)	NULL
A	NULL
gene	NULL
coding	NULL
for	NULL
a	NULL
protein	NULL
possessing	NULL
shared	NULL
tumor	NULL
epitopes	NULL
capable	NULL
of	NULL
inducing	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
in	NULL
cancer	NULL
patients	NULL
.	NULL

Cancer	NULL
Res	NULL
59	NULL
:	NULL
4056-4063	NULL
Zaks	NULL
TZ	NULL
,	NULL
and	NULL
Rosenberg	NULL
SA	NULL
(	NULL
1998	NULL
)	NULL
Immunization	NULL
with	NULL
a	NULL
peptide	NULL
epitope	NULL
(	NULL
p369-377	NULL
)	NULL
from	NULL
HER-2/neu	NULL
leads	NULL
to	NULL
peptide-specificity	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
that	NULL
fail	NULL
to	NULL
recognize	NULL
HER-2/neu*	NULL
tumors	NULL
.	NULL

Cancer	NULL
Res	NULL
58	NULL
:	NULL
4902-4908	NULL
British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
2001	NULL
)	NULL
84	NULL
(	NULL
7	NULL
)	NULL
,	NULL
915-919	NULL

